Doxorubicin nanoformulations on therapy against cancer: An overview from the last 10 years.
D'Angelo NA, Noronha MA, Câmara MCC, Kurnik IS, Feng C, Araujo VHS, Santos JHPM, Feitosa V, Molino JVD, Rangel-Yagui CO, Chorilli M, Ho EA, Lopes AM.
D'Angelo NA, et al. Among authors: chorilli m.
Biomater Adv. 2022 Feb;133:112623. doi: 10.1016/j.msec.2021.112623. Epub 2021 Dec 23.
Biomater Adv. 2022.
PMID: 35525766
Review.